
Take Q1 FY20 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- TAKE Solutions closed the previous year at $292 million in revenue.
- For FY2020, they expect to reach closer to $370-380 million, possibly surpassing this.
- The company targets a long-term vision of reaching $0.5 billion in topline revenue.
- Growth is currently above industry standards, though the high historic CQGR of around 8% may not be sustained indefinitely.
- Recent acquisitions (KAI Research and DataCeutics) are progressing well, expected to contribute increasingly to consolidated growth.
- The company is pursuing larger deals, with some potential contracts valued above $10 million, and up to $25 million.
- Expansion of multi-country clinical trials is driving growth opportunities.
- Capacity utilization is currently around 55%, and as it improves, revenue growth and cash flow generation are expected to accelerate further.
See what Take management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No fresh loans were taken during the quarter; only normal maturities and working capital limits were used.
- There was no loan maturity during the quarter other than normal working capital repayments.
- The company currently does not indicate any immediate plans for raising new debt.
- Management focus is on investing for growth rather than raising capital through buybacks or fundraising.
- Capital expenditure for FY2020 is budgeted around 120 Crores, including asset investments and some possible intangible capitalizations.
- No mention of any planned equity fundraising or share buyback initiatives at this time; management prefers investing in business growth.
See what Take management said on order book — free account, 30 seconds.
Capex plans
Yes- TAKE Solutions expects a total Capex of about 120 Crores for the fiscal year, including investments in tangible assets such as facilities, replacements, and refurbishments.
- In Q1 FY2020, the company invested around 20 to 22 Crores in Capex.
- Intangible asset investments (including IP) have been muted in the past two years; however, ongoing work might lead to some capitalization during the year.
- Future investments and Capex will depend on growth and order book levels.
- The company is investing in capacity creation to support revenue growth, currently at about 55% utilization, expecting improvements over the next two years.
- Additional Capex is also targeted towards offshoring initiatives in newly acquired entities to improve margins.
Track Take — get its next earnings analysis in your feed
How does Take rank vs peers in Healthcare Services?
Pro featureHow does Take rank in Healthcare Services?
Compare Take against every Healthcare Services company (Q1 FY20) on revenue, margins and earnings-call signals.
Continue your research
What Take's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.